Detalles de la búsqueda
1.
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Breast Cancer Res
; 23(1): 38, 2021 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33761970
2.
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Breast Cancer Res Treat
; 170(2): 329-341, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29564743
3.
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers.
BMC Med
; 13: 46, 2015 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-25857348
4.
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial.
JCO Precis Oncol
; 8: e2300285, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38427931
5.
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor-positive Breast Cancer.
Clin Cancer Res
; 30(9): 1889-1905, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38381406
6.
Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor-positive Breast Cancer.
Cancer Res Commun
; 3(11): 2331-2344, 2023 11 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-37921419
7.
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer.
Cancer Res
; 83(19): 3284-3304, 2023 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37450351
8.
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer.
Cancer Res
; 82(20): 3673-3686, 2022 10 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-35950920
9.
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer.
Cancers (Basel)
; 13(11)2021 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34072070
10.
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.
Cancer Treat Rev
; 93: 102136, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33360919
11.
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Clin Cancer Res
; 27(17): 4870-4882, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33536276
12.
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06).
Ther Adv Med Oncol
; 11: 1758835919891608, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31853266
13.
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer.
NPJ Breast Cancer
; 4: 38, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30511015
14.
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.
Oncotarget
; 9(23): 16389-16399, 2018 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-29662653
15.
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.
Breast Care (Basel)
; 12(5): 304-308, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-29234249
16.
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.
Oncotarget
; 7(42): 68012-68022, 2016 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27634906
17.
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer.
Clin Cancer Res
; 22(23): 5755-5764, 2016 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27185372
18.
Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Clin Cancer Res
; 27(17): 4939, 2021 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34470810
19.
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer.
Nat Rev Clin Oncol
; 12(9): 541-52, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26011489
Resultados
1 -
19
de 19
1
Próxima >
>>